New kidney innovation
For those interested in learning about a new innovation:
NephroSant is a company that has developed the first and only urine-based test for the detection of kidney transplant rejection called QSant. A personalized risk that that goes beyond a simple signal of rejection.
QSant™ detects a variety of rejection types and can be used on pediatric patients, multi-organ transplant recipients, pregnant patients, sibling and identical twin-donors, and repeat transplant patients. It generates a QScore to measure the risk of rejection which can be closely monitored over time.